Blood levels of saturated and monounsaturated fatty acids as markers of de novo lipogenesis and risk of prostate cancer

American Journal of Epidemiology

Volumn 178, Issue 8, 2013, Pages 1246-1255

  Chavarro, Jorge E ^a   Kenfield, Stacey A ^a   Stampfer, Meir J ^a   Loda, Massimo ^a   Campos, Hannia ^a   Sesso, Howard D ^a   Ma, Jing ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

biomarkers; epidemiology; fatty acids; nutrition; prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; ACYL COENZYME A DESATURASE; BETA CAROTENE; MONOUNSATURATED FATTY ACID; MYRISTIC ACID; PALMITIC ACID; PALMITOLEIC ACID; SATURATED FATTY ACID; STEARIC ACID;

BIOMARKER; BLOOD; DISEASE INCIDENCE; ENZYME ACTIVITY; FATTY ACID; GAS CHROMATOGRAPHY; GENE EXPRESSION; HEALTH STATUS; HETEROGENEITY; POLYMORPHISM; PUBLIC HEALTH;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY ACID BLOOD LEVEL; FOLLOW UP; GAS CHROMATOGRAPHY; GENE FREQUENCY; GENETIC VARIABILITY; GLEASON SCORE; HEART DISEASE; HOMOZYGOTE; HUMAN; INCIDENCE; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; OXIDATION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; WILD TYPE;

BIOMARKERS; EPIDEMIOLOGY; FATTY ACIDS; NUTRITION; PROSTATE CANCER;

BIOLOGICAL MARKERS; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; HUMANS; INCIDENCE; LIPOGENESIS; LOGISTIC MODELS; MALE; PROSTATIC NEOPLASMS;

EID: 84885823450     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt136     Document Type: Article

References (39)

1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta: American Cancer Society; 2012:19-20.
2. Baylin A, Kim MK, Donovan-Palmer A, et al. Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. Am J Epidemiol. 2005;162(4):373-381. (Pubitemid 41389719)
3. Sun Q, Ma J, Campos H, et al. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin Nutr. 2007;86(1):74-81. (Pubitemid 47041595)
4. Chavarro JE, Stampfer MJ, Li H, et al. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16(7): 1364-1370. (Pubitemid 47076865)
5. Chavarro JE, Stampfer MJ, Campos H, et al. A prospective study of trans-fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(1): 95-101. (Pubitemid 351196278)
6. Vega-Lopez S, Ausman LM, Jalbert SM, et al. Palm and partially hydrogenated soybean oils adversely alter lipoprotein profiles compared with soybean and canola oils in moderately hyperlipidemic subjects. Am J Clin Nutr. 2006;84 (1):54-62. (Pubitemid 44699171)
7. Tholstrup T, Raff M, Basu S, et al. Effects of butter high in ruminant trans and monounsaturated fatty acids on lipoproteins, incorporation of fatty acids into lipid classes, plasma C-reactive protein, oxidative stress, hemostatic variables, and insulin in healthy young men. Am J Clin Nutr. 2006;83(2):237-243. (Pubitemid 44713183)
8. Lichtenstein AH, Erkkila AT, Lamarche B, et al. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis. 2003;171(1):97-107. (Pubitemid 37464634)
9. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002; 98(1):19-22. (Pubitemid 34113412)
10. Rossi S, Graner E, Febbo P, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1(10):707-715. (Pubitemid 37025589)
11. Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010;28(25): 3958-3964.
12. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3): 129-135.
13. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334(18):1145-1149. (Pubitemid 26137972)
14. Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst. 1994;86(4):281-286. (Pubitemid 24057406)
15. Zock PL, Gerristen J, Katan M. Partial conservation of the sn-2 position of dietary triglicerides in fasting plasma lipids in humans. Eur J Clin Invest. 1996;26(2):141-150. (Pubitemid 26063438)
16. Zock PL, Mensink RP, Harryvan J, et al. Fatty acids in serum cholesteryl esters as quantitative biomarkers of dietary intake in humans. Am J Epidemiol. 1997;145(12): 1114-1122. (Pubitemid 27272941)
17. Zeleniuch-Jacquotte A, Chajes V, Van Kappel AL, et al. Reliability of fatty acid composition in human serum phospholipids. Eur J Clin Nutr. 2000;54(5):367-372. (Pubitemid 30261386)
18. Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer. 2000;88(2):176-179.
19. Shah US, Dhir R, Gollin SM, et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol. 2006;37(4):401-409.
20. Bandyopadhyay S, Pai SK,Watabe M, et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene. 2005;24(34):5389-5395. (Pubitemid 43080109)
21. Kuhajda FP, Jenner K,Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 1994;91(14):6379-6383. (Pubitemid 24200664)
22. Pizer ES, Jackisch C,Wood FD, et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 1996;56(12):2745-2747. (Pubitemid 26175731)
23. ZhouW, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 2003;63(21):7330-7337. (Pubitemid 37413474)
24. De Schrijver E, Brusselmans K, HeynsW, et al. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 2003;63(13):3799-3804. (Pubitemid 36793069)
25. Brusselmans K, De Schrijver E, Verhoeven G, et al. RNA interference-mediated silencing of the acetyl-CoAcarboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 2005;65(15): 6719-6725. (Pubitemid 41060709)
26. Li JN, Gorospe M, Chrest FJ, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 2001;61(4): 1493-1499. (Pubitemid 34292578)
27. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039-1047.
28. Cao H, Gerhold K, Mayers JR, et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134(6):933-944.
29. Koeberle A, Shindou H, Harayama T, et al. Palmitoleate is a mitogen, formed upon stimulation with growth factors, and converted to palmitoleoyl-phosphatidylinositol. J Biol Chem. 2012;287(32):27244-27254.
30. Gong J, Campos H, McGarvey S, et al. Adipose tissue palmitoleic acid and obesity in humans: does it behave as a lipokine? Am J Clin Nutr. 2011;93(1):186-191.
31. Hodson L, Karpe F. Is there something special about palmitoleate? Curr Opin Clin Nutr Metab Care. 2013; 16(2):225-231.
32. Crowe FL, Allen NE, Appleby PN, et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2008;88(5):1353-1363.
33. Jackson MD,Walker SP, Simpson-Smith CM, et al. Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. Cancer Causes Control. 2012;23(1):23-33.
34. Park SY,Wilkens LR, Henning SM, et al. Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control. 2009;20(2): 211-223.
35. Mannisto S, Pietinen P, Virtanen MJ, et al. Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Cancer Epidemiol Biomarkers Prev. 2003;12(12): 1422-1428. (Pubitemid 38031744)
36. Shannon J, O'Malley J, Mori M, et al. Erythrocyte fatty acids and prostate cancer risk: a comparison of methods. Prostaglandins Leukot Essent Fatty Acids. 2010;83(3): 161-169.
37. Ukoli FA, Fowke JH, Akumabor P, et al. The association of plasma fatty acids with prostate cancer risk in African Americans and Africans. J Health Care Poor Underserved. 2010;21(1 suppl):127-147.
38. Harvei S, Bjerve KS, Tretli S, et al. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer. 1997;71(4): 545-551. (Pubitemid 27239362)
39. Shannon J, King IB, Moshofsky R, et al. Erythrocyte fatty acids and breast cancer risk: a case-control study in Shanghai, China. Am J Clin Nutr. 2007;85(4): 1090-1097.